These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

465 related items for PubMed ID: 15240541

  • 1. Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression.
    Ballangrud AM, Yang WH, Palm S, Enmon R, Borchardt PE, Pellegrini VA, McDevitt MR, Scheinberg DA, Sgouros G.
    Clin Cancer Res; 2004 Jul 01; 10(13):4489-97. PubMed ID: 15240541
    [Abstract] [Full Text] [Related]

  • 2. Cytotoxicity of breast cancer cells overexpressing HER2/neu by 213Bi-Herceptin radioimmunoconjugate.
    Zhang DY, Li Y, Rizvi SM, Qu C, Kearsley J, Allen BJ.
    Cancer Lett; 2005 Feb 10; 218(2):181-90. PubMed ID: 15670895
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction.
    Akabani G, Carlin S, Welsh P, Zalutsky MR.
    Nucl Med Biol; 2006 Apr 10; 33(3):333-47. PubMed ID: 16631082
    [Abstract] [Full Text] [Related]

  • 5. [Effects of interferon-gamma on Her-2/neu expression and antitumor activity of 131I-Herceptin in breast cancer cell lines].
    Fan YX, Luo RC, Fang YX, Yan X, Lu CW.
    Ai Zheng; 2006 Apr 10; 25(4):443-6. PubMed ID: 16613677
    [Abstract] [Full Text] [Related]

  • 6. Targeted actinium-225 in vivo generators for therapy of ovarian cancer.
    Borchardt PE, Yuan RR, Miederer M, McDevitt MR, Scheinberg DA.
    Cancer Res; 2003 Aug 15; 63(16):5084-90. PubMed ID: 12941838
    [Abstract] [Full Text] [Related]

  • 7. Evaluating the potential of 188Re-SOCTA-trastuzumab as a new radioimmunoagent for breast cancer treatment.
    Luo TY, Tang IC, Wu YL, Hsu KL, Liu SW, Kung HC, Lai PS, Lin WJ.
    Nucl Med Biol; 2009 Jan 15; 36(1):81-8. PubMed ID: 19181272
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. 188Re-HYNIC-trastuzumab enhances the effect of apoptosis induced by trastuzumab in HER2-overexpressing breast cancer cells.
    Luo TY, Cheng PC, Chiang PF, Chuang TW, Yeh CH, Lin WJ.
    Ann Nucl Med; 2015 Jan 15; 29(1):52-62. PubMed ID: 25238789
    [Abstract] [Full Text] [Related]

  • 10. Retargeting of adenoviral gene delivery via Herceptin-PEG-adenovirus conjugates to breast cancer cells.
    Jung Y, Park HJ, Kim PH, Lee J, Hyung W, Yang J, Ko H, Sohn JH, Kim JH, Huh YM, Yun CO, Haam S.
    J Control Release; 2007 Nov 06; 123(2):164-71. PubMed ID: 17854941
    [Abstract] [Full Text] [Related]

  • 11. HER2/neu reduces the apoptotic effects of N-(4-hydroxyphenyl)retinamide (4-HPR) in breast cancer cells by decreasing nitric oxide production.
    Simeone AM, Broemeling LD, Rosenblum J, Tari AM.
    Oncogene; 2003 Oct 02; 22(43):6739-47. PubMed ID: 14555987
    [Abstract] [Full Text] [Related]

  • 12. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
    Menendez JA, Vellon L, Lupu R.
    Med Hypotheses; 2005 Oct 02; 64(5):997-1001. PubMed ID: 15780499
    [Abstract] [Full Text] [Related]

  • 13. Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines.
    Gong SJ, Jin CJ, Rha SY, Chung HC.
    Cancer Lett; 2004 Oct 28; 214(2):215-24. PubMed ID: 15363548
    [Abstract] [Full Text] [Related]

  • 14. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
    Esteva FJ, Cheli CD, Fritsche H, Fornier M, Slamon D, Thiel RP, Luftner D, Ghani F.
    Breast Cancer Res; 2005 Oct 28; 7(4):R436-43. PubMed ID: 15987448
    [Abstract] [Full Text] [Related]

  • 15. Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/neu oncoprotein.
    Sato S, Kajiyama Y, Sugano M, Iwanuma Y, Sonoue H, Matsumoto T, Sasai K, Tsurumaru M.
    Int J Radiat Oncol Biol Phys; 2005 Jan 01; 61(1):203-11. PubMed ID: 15629613
    [Abstract] [Full Text] [Related]

  • 16. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.
    Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L.
    Semin Oncol; 1999 Aug 01; 26(4 Suppl 12):78-83. PubMed ID: 10482197
    [Abstract] [Full Text] [Related]

  • 17. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH, Wang YC, Weng SC, Weng JR, Chen CS, Brueggemeier RW, Shapiro CL, Chen CY, Dunn SE, Pollak M, Chen CS.
    Mol Pharmacol; 2006 Nov 01; 70(5):1534-41. PubMed ID: 16887935
    [Abstract] [Full Text] [Related]

  • 18. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
    Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA.
    Semin Oncol; 1999 Aug 01; 26(4 Suppl 12):60-70. PubMed ID: 10482195
    [Abstract] [Full Text] [Related]

  • 19. (111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer.
    Costantini DL, Chan C, Cai Z, Vallis KA, Reilly RM.
    J Nucl Med; 2007 Aug 01; 48(8):1357-68. PubMed ID: 17631548
    [Abstract] [Full Text] [Related]

  • 20. HER2-specific cytotoxic activity of lymphokine-activated killer cells in the presence of trastuzumab.
    Yamaguchi Y, Hironaka K, Okawaki M, Okita R, Matsuura K, Ohshita A, Toge T.
    Anticancer Res; 2005 Aug 01; 25(2A):827-32. PubMed ID: 15868915
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.